Glucovance: Advanced Dual-Action Therapy for Type 2 Diabetes Management
| Product dosage: 2.5mg/400mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.38 | $41.28 (0%) | 🛒 Add to cart |
| 60 | $1.16 | $82.56 $69.66 (16%) | 🛒 Add to cart |
| 90 | $1.06 | $123.84 $95.46 (23%) | 🛒 Add to cart |
| 120 | $1.00 | $165.12 $119.54 (28%) | 🛒 Add to cart |
| 180 | $0.93 | $247.68 $166.84 (33%) | 🛒 Add to cart |
| 270 | $0.86 | $371.52 $232.20 (38%) | 🛒 Add to cart |
| 360 | $0.69
Best per pill | $495.36 $247.68 (50%) | 🛒 Add to cart |
| Product dosage: 5mg/500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.46 | $43.86 (0%) | 🛒 Add to cart |
| 60 | $1.29 | $87.72 $77.40 (12%) | 🛒 Add to cart |
| 90 | $1.20 | $131.58 $108.36 (18%) | 🛒 Add to cart |
| 120 | $1.15 | $175.44 $137.60 (22%) | 🛒 Add to cart |
| 180 | $1.09 | $263.16 $196.08 (25%) | 🛒 Add to cart |
| 270 | $1.03 | $394.74 $278.64 (29%) | 🛒 Add to cart |
| 360 | $0.82
Best per pill | $526.32 $294.12 (44%) | 🛒 Add to cart |
Glucovance represents a significant advancement in the pharmacological management of type 2 diabetes mellitus, combining two established antihyperglycemic agents into a single, convenient tablet. This fixed-dose combination therapy synergistically targets two key pathophysiological defects of the disease: insulin resistance and impaired insulin secretion. By addressing both hepatic glucose production and peripheral glucose uptake, Glucovance offers clinicians a powerful tool for achieving and maintaining glycemic control. Its well-established efficacy and safety profile make it a cornerstone therapy in modern diabetes treatment protocols.
Features
- Contains metformin hydrochloride and glyburide in fixed-dose combinations
- Available in strengths: 1.25 mg/250 mg, 2.5 mg/500 mg, and 5 mg/500 mg
- Dual mechanism of action targeting insulin resistance and insulin secretion
- Film-coated tablets for ease of administration
- Bioequivalent to individual components administered concurrently
- Manufactured under strict quality control standards
- Temperature-stable formulation
- Child-resistant packaging available
Benefits
- Superior glycemic control compared to monotherapy with either component alone
- Reduced pill burden through combination therapy, enhancing medication adherence
- Comprehensive glucose management addressing both fasting and postprandial hyperglycemia
- Potential weight neutrality compared to some other antidiabetic regimens
- Established long-term safety profile with extensive clinical experience
- Flexible dosing options allowing for individualized treatment approaches
Common use
Glucovance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both glyburide and metformin is appropriate. It is typically prescribed when monotherapy with metformin or a sulfonylurea has provided inadequate glycemic control. The medication is particularly useful for patients who would benefit from the complementary mechanisms of action of these two agents. Clinical studies have demonstrated that Glucovance provides better glycemic control than either component alone, with many patients achieving target HbA1c levels below 7%.
Dosage and direction
The recommended starting dose of Glucovance is based on the patient’s current regimen of metformin and/or glyburide. For patients not currently treated with metformin or glyburide, the recommended starting dose is Glucovance 1.25 mg/250 mg once daily with a meal. Dosage adjustments should be made in increments of no more than 5 mg glyburide/500 mg metformin daily, with adjustments made every two weeks based on glycemic control. The maximum recommended daily dose is 20 mg glyburide/2000 mg metformin. Tablets should be swallowed whole with meals to reduce gastrointestinal side effects. Renal function should be assessed before initiation and regularly during treatment.
Precautions
Glucovance carries a boxed warning regarding the risk of lactic acidosis associated with metformin use, particularly in patients with renal impairment. Regular monitoring of renal function is essential. Hypoglycemia may occur, especially when caloric intake is deficient, after strenuous exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used. Periodic monitoring of blood glucose and HbA1c is recommended. Vitamin B12 levels should be monitored periodically with prolonged metformin use. Use with caution in elderly patients, those with hepatic impairment, and patients undergoing radiologic studies involving intravascular iodinated contrast materials.
Contraindications
Glucovance is contraindicated in patients with: renal disease or renal dysfunction (serum creatinine levels ≥1.5 mg/dL in males or ≥1.4 mg/dL in females); acute or chronic metabolic acidosis, including diabetic ketoacidosis; history of hypersensitivity to metformin, glyburide, or other sulfonylureas; acute congestive heart failure requiring pharmacologic treatment; and during periods of stress such as fever, trauma, infection, or surgery. It should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Possible side effects
The most common adverse reactions (>5%) include: hypoglycemia, nausea, diarrhea, and headache. Other reported side effects include: upper respiratory infection, dizziness, asthenia, abdominal pain, and vomiting. Lactic acidosis, though rare, is a serious metabolic complication that can occur due to metformin accumulation. Hematologic effects such as leukopenia, thrombocytopenia, and hemolytic anemia have been reported with sulfonylureas. Allergic skin reactions including rash, pruritus, and urticaria may occur. Gastrointestinal symptoms are most common during initiation and typically resolve with continued therapy.
Drug interaction
Glucovance has numerous potential drug interactions. Drugs that may increase hypoglycemic risk include: insulin, other oral antidiabetic agents, ACE inhibitors, beta-blockers, fibrates, fluoxetine, MAO inhibitors, salicylates, and sulfonamide antibiotics. Drugs that may reduce efficacy include: corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. Cationic drugs that are eliminated by renal tubular secretion may interact with metformin. Alcohol potentiates the effects of metformin on lactate metabolism and increases risk of hypoglycemia.
Missed dose
If a dose of Glucovance is missed, it should be taken as soon as remembered with food, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistent timing of administration helps maintain stable blood glucose levels. Healthcare providers should educate patients on proper management of missed doses to prevent both hyperglycemia and hypoglycemia.
Overdose
Overdose of Glucovance may produce hypoglycemia, though metformin overdose alone may not cause hypoglycemia. Symptoms of hypoglycemia include: hunger, nausea, tremor, sweating, tachycardia, and confusion that may progress to convulsions, coma, and death. Treatment involves immediate glucose administration, intravenous dextrose, or glucagon injection. Metformin overdose may cause lactic acidosis, characterized by elevated blood lactate levels, decreased blood pH, electrolyte disturbances, and hypothermia. Hemodialysis may be necessary to correct metformin accumulation and acid-base imbalance. Hospitalization and close monitoring are essential for suspected overdose.
Storage
Store Glucovance tablets at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep container tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use tablets that are discolored or show signs of deterioration. Proper storage ensures medication stability and efficacy throughout the shelf life. Do not flush medications down the toilet or pour into a drain unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Glucovance should be used only under the supervision of a qualified healthcare provider. Patients should not initiate, adjust, or discontinue medication without consulting their physician. Individual response to therapy may vary, and treatment should be tailored to each patient’s specific medical condition and response. The full prescribing information should be consulted before initiating therapy.
Reviews
Clinical studies demonstrate that Glucovance provides significant improvements in glycemic control compared to monotherapy components. In a 24-week randomized trial, patients receiving Glucovance achieved mean HbA1c reductions of 2.5% compared to 1.5% with metformin alone and 1.7% with glyburide alone. Patient satisfaction surveys indicate improved quality of life due to reduced pill burden and better glucose control. Many endocrinologists report successful long-term management of type 2 diabetes with Glucovance, particularly in patients who have failed monotherapy. The combination therapy has maintained its position in treatment guidelines due to its proven efficacy and cost-effectiveness.